Endo Pharm Flashcards
Long acting Insulins
Glargine, Detemir
Glitazones/Thiazolidinediones
“Glitazone”
Pioglitazone, Rosiglitazone
DPP-4 Inhibitors
“Gliptin”
- Linagliptin, Saxagliptin, Sitagliptin
Rapid Acting Insulins
Lispro, Aspart, Glulisine
Sulfonylureas
- First Gen: Tolbutamide, Chlorpropamide
- Second Gen: Glyburide, Glimepiride, Glipizide
Amylin Analogs
Pramlintide (Injectable)
Short Acting/Intermediate Insulins
Regular and NPH
Biguanides
Metformin
alpha-glucosidase inhibitors
Acarbose, Miglitol
GLP-1 Analogs
Exenatide, Liraglutide (Injectable)
Mech: Binds to PPAR-gamma nuclear transcription receptor to increase insulin sensitivity in peripheral tissue.
Glitazones/Thiazolidinediones
Mech: Increases insulin and decreases glucagon release.
GLP-1 Analogs and DPP-4 Inhibitors
Mech: Binds insulin receptor (tyrosine kinase activity) to increase glucose stored as glycogen in liver, increase glycogen and protein synthesis while increasing K+ uptake in muscles, and to aid TG storage in fat.
Insulin
Mech: Exact unknown, decreases gluconeogenesis, increases glycolysis, increases peripheral glucose uptake (insulin sensitivity)
Biguanides (Metformin)
Mech: Inhibit intestinal brush-border alpha glucosidases.
Alpha-glucosidase inhibitors
Mech: Delayed sugar hydrolysis and glucose absorption leads to decreased postprandial hyperglycemia.
Alpha-glucosidase inhibitors
Mech: Decreases glucagon
Amylin analogs (Pramlintide)
Mech: Closes K+ channel in Beta cell membrane, so cell depolarizes leading to insulin release via increased Ca2+ influx.
Sulfonylureas
First line in type 2 DM. (Oral)
Metformin
Used for Type 2 DM as mono therapy or in combination
Glitazones/Thiazolidinediones, alpha-glucosidase inhibitors
Used for Type 1 and Type 2 DM
Amylin Analogs